Valuation: Sutro Biopharma, Inc.

Market Cap 349M 299M 280M 256M 480M 33.38B 487M 3.3B 1.29B 16.77B 1.31B 1.28B 55.46B P/E 2026 *
-2.56x
P/E 2027 * -3.18x
Enterprise Value 349M 299M 280M 256M 480M 33.38B 487M 3.3B 1.29B 16.77B 1.31B 1.28B 55.46B EV / Sales 2026 *
6.77x
EV / Sales 2027 * 11x
Free-Float
97.74%
Yield 2026 *
-
Yield 2027 * -
1 day-0.57%
1 week+2.73%
Current month-12.95%
1 month-8.52%
3 months-31.29%
6 months+14.22%
Current year+81.85%
1 week 20.21
Extreme 20.21
23.45
1 month 18.36
Extreme 18.365
26.35
Current year 10.15
Extreme 10.15
43.85
1 year 7.15
Extreme 7.15
43.85
3 years 5.23
Extreme 5.231
61.3
5 years 5.23
Extreme 5.231
237
10 years 5.23
Extreme 5.231
283
Manager TitleAgeSince
Chief Executive Officer 55 2025-03-12
Director of Finance/CFO 53 2025-06-01
Chief Tech/Sci/R&D Officer - 2025-12-31
Director TitleAgeSince
Director/Board Member 70 2009-07-31
Director/Board Member 67 2017-01-31
Director/Board Member 51 2018-07-24
Date Insider Type Main position Quantity % Market Cap.
3/1/26 Fiscal year

Chief Technology Officer

54,569 0.3330%
3/1/26 Fiscal year

Chief Administrative Officer

46,717 0.2851%
3/1/26 Fiscal year

Chief Executive Officer

240,926 1.4702%
Change 5-day change 1-year change 3-year change Capi.($)
-0.57%+2.73%+148.23%-54.56% 349M
-3.00%+2.27%+77.60%+109.33% 72.12B
+1.90%+23.53%+56.60%+97.76% 65.85B
+5.12%+25.22%+5.24%-0.82% 29.28B
+0.55%+1.64%-5.15%+471.68% 27.47B
+2.74%+12.98%+62.84%+28.14% 26.7B
+0.47%+6.12%+36.66%-13.79% 20.06B
+1.82%-6.67%+247.46%+393.10% 18.22B
+0.94%+3.36%+18.55%+532.94% 16.4B
+0.73%+5.54%+39.71%+153.07% 13.4B
Average +1.07%+7.80%+68.77%+171.69% 28.98B
Weighted average by Cap. +0.74%+9.47%+59.15%+157.55%

Financials

2026 *2027 *
Net sales 51.55M 44.16M 41.32M 37.82M 70.98M 4.93B 71.92M 488M 190M 2.48B 194M 189M 8.2B 31.59M 27.06M 25.32M 23.18M 43.5M 3.02B 44.07M 299M 117M 1.52B 119M 116M 5.02B
Net income -130M -111M -104M -95.02M -178M -12.39B -181M -1.23B -478M -6.23B -486M -476M -20.59B -141M -121M -113M -103M -194M -13.47B -196M -1.33B -520M -6.76B -528M -517M -22.37B
Net Debt - -
Logo Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
Employees
128
Date Price Change Volume
26-08-21 US$21.04 -0.57% 194,679
26-08-20 US$21.16 -3.42% 154,667
26-08-19 US$21.91 -0.59% 112,457
26-08-18 US$22.04 -1.08% 522,686
26-08-17 US$22.28 +8.79% 372,912
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
21.04USD
Average target price
47.23USD
Spread / Average Target
+124.48%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. STRO Stock